Tudor I. Oprea is a distinguished figure in digital drug discovery, with over three decades of experience in knowledge management and artificial intelligence. He co-developed groundbreaking methodologies like ChemGPS and the "lead-like approach." Notable discoveries include the first GPER agonist, designated an orphan drug since 2021, and several other significant compounds. Oprea's expertise spans machine learning models in cheminformatics, drug discovery, and target biology. He led the development of DrugCentral and Pharos as part of the NIH Common Fund project and held professorship positions at esteemed institutions. Currently, he serves as CEO of Expert Systems Inc. and Professor Emeritus at UNM School of Medicine. With over 330 publications and 11 US patents, his impact on the field is profound. Explore more about his work on his Google Scholar profile: https://bit.ly/oprea_ti.